Stockscreener 앱 받기
36.87
0.99%
0.36
Harmony Biosciences Holdings Inc 주식(HRMY)의 최신 뉴스
Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation - MSN
H.C. Wainwright Remains a Buy on Harmony Biosciences Holdings (HRMY) - MSN
Trendline Breach Raises Concern for Harmony Biosciences Holdings Inc. InvestorsDay Trade & Weekly Sector Rotation Insights - beatles.ru
Mizuho Lifts Harmony Biosciences Target to $50, Citing Confidence in Fragile X Trial - Insider Monkey
Harmony Biosciences Holdings Inc. Stock Poised for Technical ComebackJuly 2025 Patterns & Verified Momentum Stock Ideas - sundaytimes.kr
Harmony Biosciences Delivers Strong Q2 Growth, Advances Late-Stage Pipeline - MSN
10 Best Cheap Growth Stocks to Buy According to Analysts - Insider Monkey
Mizuho Securities Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
Mizuho raises Harmony Biosciences stock price target to $50 on increased confidence - Investing.com Canada
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $50 at Mizuho - StreetInsider
Relief Rally in Harmony Biosciences Holdings Inc. Stock — Can It HoldEarly Entry Tips With Low Risk Zone Shared - beatles.ru
SIXS ETF Implied Analyst Target Price: $58.24 - AInvest
Harmony Biosciences Earnings Call Highlights Growth and Innovation - The Globe and Mail
Harmony Biosciences Holdings Inc: A Financial Analysis of Growth and Strategic Positioning - AInvest
Harmony Biosciences Reports Strong Q2 Revenue Growth, Reaffirms 2025 Guidance, and Prepares to Announce Fragile X Trial Data in Q3 - AInvest
Harmony Biosciences Holdings: Buy Rating Maintained Despite Q2 Earnings Miss - AInvest
Harmony targets $1B+ WAKIX sales in narcolepsy as late-stage pipeline advances - MSN
Harmony Biosciences Holdings Reports Q2 2025 Earnings: Revenue Up 16% - AInvest
Harmony Biosciences Holdings Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Harmony Biosciences Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2025 Earnings Call Transcript - Insider Monkey
Three Stocks to Buy Now: Harmony Biosciences, Syndax Pharmaceuticals, and Viper Energy - AInvest
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 - BioSpace
Harmony Biosciences Holdings, Inc. (HRMY): A Bullish Thesis on Strong Financials and Diversified Pipeline - AInvest
Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... - Investing.com Canada
Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Call Hi - GuruFocus
Decoding Harmony Biosciences Holdings Inc (HRMY): A Strategic SW - GuruFocus
Harmony Biosciences' Q2 2025: Unraveling Contradictions in ZYN002 and WAKIX Strategies - AInvest
Harmony Biosciences Holdings, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:HRMY) - Seeking Alpha
Transcript : Harmony Biosciences Holdings, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Earnings call transcript: Harmony Biosciences Q2 2025 beats EPS expectations - Investing.com Canada
Harmony Biosciences Holdings: Strong Patient Growth and Promising Pipeline Support Buy Rating - TipRanks
Harmony Biosciences falls as Q2 revenue misses estimates despite profit beat - Investing.com Nigeria
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates - Yahoo Finance
Why Harmony Biosciences Holdings Inc. stock attracts strong analyst attentionSafe Entry Stock Watch Suggestions for Cautious Traders - beatles.ru
Harmony Biosciences Holdings, Inc. SEC 10-Q Report - TradingView
Harmony Biosciences Q2 2025 slides: revenue up 16% as WAKIX nears blockbuster status - Investing.com Canada
Topline Data from the Phase 3 registrational trial of ZYN002 in Fragile X syndrome on track for Q3 2025. - Placera.se
Harmony Biosciences : HRMY Q2 2025 Earnings Presentation FINAL - MarketScreener
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 | HRMY Stock - GuruFocus
Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory - Insider Monkey
Harmony Biosciences Holdings Inc. Stages Intraday Comeback — Trend ChangeSecure Portfolio Growth Plan Review - beatles.ru
Harmony Biosciences Holdings Inc (HRMY) Q2 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Trading Bots Trigger Alerts on Harmony Biosciences Holdings Inc. ActivityMassive Profit Potential - beatles.ru
Published on: 2025-08-04 07:58:17 - metal.it
Is Harmony Biosciences Holdings Inc. stock overvalued or undervaluedMaximize gains with proven stock analysis - Jammu Links News
What are analysts’ price targets for Harmony Biosciences Holdings Inc. in the next 12 monthsAchieve consistent double-digit returns - Jammu Links News
Why is Harmony Biosciences Holdings Inc. stock attracting strong analyst attentionUnlock your trading potential with expert tips - Jammu Links News
What catalysts could drive Harmony Biosciences Holdings Inc. stock higher in 2025 - Jammu Links News
Harmony Biosciences Holdings Inc. Stock Analysis and ForecastTriple-digit returns - Jammu Links News
0.41%
0.88%
자본화:
|
볼륨(24시간):